
  
    
      
        Background_NNP
        It_PRP was_VBD originally_RB thought_VBN that_IN GPCRs_NNP and_CC tyrosine_NN kinase_NN
        receptors_NNS functioned_VBD independently_RB to_TO mediate_VB different_JJ
        signaling_VBG events_NNS ,_, but_CC it_PRP has_VBZ become_VBN clear_JJ in_IN recent_JJ years_NNS
        that_IN some_DT functions_NNS and_CC signaling_VBG pathways_NNS are_VBP shared_VBN (_( for_IN
        reviews_NNS ,_, see_VB Marinissen_NNP and_CC Gutkind_NNP ,_, 2001_CD [_NN 1_CD ]_NN ;_: Luttrell_NNP ,_,
        2002_CD [_NN 2_CD ]_NN ;_: and_CC van_NN Biesen_NNP et_CC al_NN ._. ,_, 1996_CD [_NN 3_CD ]_NN )_) ._. For_IN
        example_NN ,_, some_DT classical_JJ neurotransmitters_NNS such_JJ as_IN 5_CD -_: HT_NNP have_VBP
        short-term_JJ effects_NNS on_IN ion_NN channels_NNS and_CC other_JJ effectors_NNS such_JJ
        as_IN adenylyl_NN cyclase_NN but_CC also_RB have_VBP growth_NN factor-like_JJ
        effects_NNS in_IN developing_VBG brain_NN [_NN 4_CD ]_NN and_CC mitogenic_JJ effects_NNS on_IN
        fibroblasts_NNS (_( reviewed_VBN in_IN Gerhardt_NNP and_CC van_NN Heerikhuizen_NNP ,_,
        1997_CD [_NN 5_CD ]_NN )_) ._. The_DT peptide_NN hormones_NNS insulin_NN and_CC IGF-_NNP 1_CD have_VBP
        both_DT short-term_JJ metabolic_JJ effects_NNS and_CC long-term_JJ actions_NNS on_IN
        cell_NN growth_NN and_CC differentiation_NN ._. Insulin_NNP and_CC IGF-I_NNP bind_NN and_CC
        stimulate_VB tyrosine_NN kinase_NN receptors_NNS which_WDT interact_NN with_IN a_DT
        large_JJ number_NN of_IN effectors_NNS [_NN 6_CD 7_CD ]_NN ._. Complex_JJ interactions_NNS
        occur_VBP between_IN these_DT two_CD types_NNS of_IN signaling_VBG pathways_NNS that_WDT
        are_VBP the_DT subject_NN of_IN intense_JJ investigation_NN ._.
        The_DT 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN displays_VBZ a_DT heterogeneous_JJ
        distribution_NN in_IN the_DT CNS_NNP [_NN 8_CD ]_NN and_CC is_VBZ not_RB found_VBN in_IN
        peripheral_JJ tissues_NNS ._. It_PRP is_VBZ abundant_JJ in_IN choroid_NN plexus_JJ where_WRB
        it_PRP modulates_NNS the_DT production_NN of_IN cerebrospinal_NN fluid_JJ (_( CSF_NNP )_) ,_,
        and_CC in_IN limbic_JJ regions_NNS and_CC hypothalamus_JJ where_WRB it_PRP may_MD play_VB a_DT
        role_NN in_IN motor_NN behavior_NN and_CC appetite_NN control_NN ._. The_DT 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN has_VBZ been_VBN implicated_VBN in_IN
        anxiety_NN ,_, migraine_NN ,_, movement_NN disorders_NNS ,_, eating_VBG disorders_NNS and_CC
        neuroendocrine_NN regulation_NN [_NN 9_CD ]_NN ._. The_DT importance_NN of_IN the_DT
        5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN in_IN regulation_NN of_IN food_NN intake_NN
        is_VBZ evident_JJ in_IN a_DT knockout_NN mouse_NN developed_VBN by_IN Tecott_NNP et_CC al_NN ._. [_NN
        10_CD ]_NN ._. The_DT obesity_NN found_VBD in_IN these_DT mice_NNS is_VBZ due_JJ to_TO excessive_JJ
        food_NN intake_NN and_CC this_DT phenotype_NN along_IN with_IN increased_VBN plasma_NN
        levels_NNS of_IN insulin_NN and_CC leptin_NN is_VBZ analogous_JJ to_TO Type_NNP 2_CD
        diabetes_NN ._. The_DT knockout_NN mouse_NN is_VBZ also_RB susceptible_JJ to_TO
        epileptic-like_JJ seizures_NNS -_: suggesting_VBG that_IN the_DT 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN has_VBZ a_DT role_NN in_IN tonic_NN
        inhibition_NN of_IN neuronal_NN excitability_NN ._.
        5_LS -_: HT_NNP 
        2_CD C_NNP receptors_NNS and_CC insulin_NN /_NN IGF-_NNP 1_CD receptors_NNS
        share_VBP some_DT functional_JJ roles_NNS ;_: both_DT have_VBP trophic_JJ effects_NNS in_IN
        the_DT brain_NN and_CC modulate_VBP appetite_NN ._. 5_LS -_: HT_NNP 
        2_CD C_NNP receptors_NNS [_NN 8_CD ]_NN and_CC insulin_NN /_NN IGF-_NNP 1_CD
        receptors_NNS [_NN 11_CD ]_NN co-localize_JJ in_IN several_JJ areas_NNS in_IN the_DT brain_NN
        including_VBG choroid_NN plexus_JJ ,_, olfactory_NN bulb_NN ,_, cerebral_JJ cortex_NN ,_,
        hypothalamus_JJ ,_, and_CC hippocampus_JJ ._. Interactions_NNP between_IN insulin_NN
        and_CC serotonergic_JJ pathways_NNS may_MD have_VB important_JJ consequences_NNS
        for_IN their_PRP$ known_VBN roles_NNS in_IN appetite_NN modulation_NN and_CC trophic_JJ
        actions_NNS in_IN the_DT brain_NN ._. We_PRP chose_VBD to_TO look_VB for_IN these_DT types_NNS of_IN
        interactions_NNS in_IN choroid_NN plexus_JJ because_IN both_DT 5_CD -_: HT_NNP 
        2_CD C_NNP receptors_NNS and_CC insulin_NN /_NN IGF-_NNP 1_CD receptors_NNS
        are_VBP abundant_JJ in_IN this_DT tissue_NN and_CC because_IN the_DT 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN is_VBZ the_DT only_RB 5_CD -_: HT_NNP receptor_NN
        present_JJ in_IN these_DT cells_NNS ._.
        The_DT 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN is_VBZ a_DT member_NN of_IN the_DT GPCR_NNP
        family_NN ._. GPCRs_NNP stimulate_VB heterotrimeric_JJ G_NNP proteins_NNS which_WDT
        release_VBP activated_VBN Gα_NNP and_CC Gβγ_NNP subunits_NNS to_TO interact_NN with_IN a_DT
        variety_NN of_IN effectors_NNS ._. The_DT function_NN of_IN GPCRs_NNP is_VBZ tightly_RB
        regulated_VBN by_IN phosphorylation_NN by_IN second_JJ messenger_NN activated_VBN
        kinases_NNS (_( protein_NN kinase_NN A_DT and_CC protein_NN kinase_NN C_NNP )_) and_CC G_NNP
        protein-coupled_JJ receptor-specific_JJ kinases_NNS (_( GRKs_NNP )_) ._. Arrestins_NNP
        bind_NN phosphorylated_JJ receptors_NNS and_CC further_JJ down-regulate_JJ
        receptor_NN activity_NN by_IN inhibiting_VBG G_NNP protein_NN interaction_NN ._. It_PRP
        is_VBZ well-known_JJ that_IN GPCRs_NNP can_MD regulate_VB the_DT activity_NN of_IN
        tyrosine_NN kinase_NN /_NN MAP_NNP kinase_NN pathways_NNS ._. However_RB ,_, there_EX is_VBZ
        little_JJ evidence_NN for_IN reciprocal_JJ regulation_NN :_: MAP_NNP kinase_NN
        effects_NNS on_IN GPCR_NNP function_NN ._. Here_RB we_PRP report_VBP such_JJ evidence_NN -_:
        insulin-mediated_JJ MAP_NNP kinase_NN regulation_NN of_IN 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN activity_NN ._.
      
      
        Results_NNS
        
          Effect_NN of_IN insulin_NN signaling_VBG on_IN 5_CD HT_NNP 2_CD Creceptor_NNP
          function_NN in_IN choroid_NN plexus_JJ cells_NNS
          We_PRP examined_VBD the_DT effects_NNS of_IN insulin_NN signaling_VBG on_IN 5_CD -_: HT_NNP 
          2_CD C_NNP receptor_NN function_NN in_IN isolated_VBN rat_NN
          choroid_NN plexus_JJ cells_NNS ._. Activation_NNP of_IN 5_CD -_: HT_NNP 
          2_CD C_NNP receptors_NNS in_IN choroid_NN plexus_JJ
          stimulates_NNS phosphoinositol_NN hydrolysis_NNS [_NN 12_CD ]_NN and_CC
          increases_NNS intracellular_NN calcium_NN [_NN 13_CD ]_NN ._. We_PRP measured_VBD
          changes_NNS in_IN intracellular_NN calcium_NN in_IN response_NN to_TO serotonin_NN
          (_( 5_CD -_: HT_NNP )_) with_IN the_DT calcium_NN indicator_NN ,_, fura_NN ._. A_DT robust_JJ
          increase_NN in_IN intracellular_NN calcium_NN was_VBD seen_VBN in_IN response_NN to_TO
          5_CD -_: HT_NNP (_( Fig_NNP ._. 1_LS aand_NN 1_CD c_SYM )_) and_CC this_DT response_NN could_MD be_VB
          completely_RB blocked_VBN with_IN the_DT selective_JJ 5_CD -_: HT_NNP 
          2_CD C_NNP receptor_NN antagonist_NN ,_, mesulergine_NN
          (_( data_NNS not_RB shown_VBN )_) ._. The_DT response_NN to_TO 5_CD -_: HT_NNP was_VBD significantly_RB
          attenuated_JJ (_( 40_CD %_NN inhibition_NN )_) when_WRB choroid_NN plexus_JJ cells_NNS
          were_VBD treated_VBN with_IN insulin_NN before_IN superfusing_VBG serotonin_NN
          (_( Fig_NNP ._. 1_LS band_NN 1_CD c_SYM )_) ._. Pretreatment_NNP with_IN PD_NNP 098059_CD ,_, a_DT MEK_NNP
          inhibitor_NN blocked_VBD the_DT inhibitory_NN effect_NN of_IN insulin_NN (_( Fig_NNP ._.
          1_LS c_SYM )_) but_CC had_VBD no_DT effect_NN on_IN the_DT serotonin_NN response_NN when_WRB used_VBN
          alone_RB ._. These_DT data_NNS indicate_VBP that_IN insulin_NN inhibits_NNS 5_CD -_: HT_NNP 
          2_CD C_NNP receptor_NN activity_NN and_CC MEK_NNP is_VBZ an_DT
          obligatory_JJ component_NN of_IN insulin_NN 's_POS action_NN ,_, implicating_VBG the_DT
          involvement_NN of_IN the_DT MAP_NNP kinase_NN pathway_NN ._.
        
        
          Characterization_NNP of_IN the_DT mechanism_NN of_IN insulin_NN 's_POS
          effect_NN on_IN 5_CD HT_NNP 2_CD Creceptor_NNP function_NN in_IN Xenopus_NNP
          oocytes_NNS
          To_TO delineate_NN the_DT mechanism_NN of_IN insulin_NN 's_POS action_NN on_IN the_DT
          5_CD -_: HT_NNP 
          2_CD C_NNP receptor_NN ,_, we_PRP used_VBD the_DT 
          Xenopus_NNP oocyte_NN expression_NN system_NN ._.
          Oocytes_NNP contain_VB endogenous_JJ insulin_NN and_CC IGF-_NNP 1_CD receptors_NNS [_NN
          14_CD ]_NN ._. They_PRP also_RB have_VBP many_JJ of_IN the_DT proteins_NNS in_IN the_DT RAS_NNP and_CC
          MAP_NNP kinase_NN pathways_NNS ,_, which_WDT have_VBP been_VBN implicated_VBN in_IN cell_NN
          cycle_NN control_NN and_CC re-entry_JJ into_IN meiosis_NNS [_NN 15_CD 16_CD ]_NN ._. ._. We_PRP
          expressed_VBD two_CD GPCRs_NNP ,_, a_DT serotonin_NN receptor_NN (_( 5_CD -_: HT_NNP 
          2_CD C_NNP )_) and_CC an_DT M_NNP 1_CD muscarinic_JJ
          acetylcholine_NN (_( Ach_NNP )_) receptor_NN ._. Both_DT receptors_NNS utilize_VB G_NNP
          proteins_NNS for_IN signaling_VBG ;_: they_PRP stimulate_VB phosphoinositide_NN
          hydrolysis_NNS and_CC increased_VBN phospholipase_NN C_NNP activity_NN which_WDT
          leads_VBZ to_TO transient_JJ activation_NN of_IN a_DT Ca_MD 2_CD +_NN -_: dependent_JJ Cl_NNP
          -_: current_JJ in_IN the_DT oocytes_NNS ._. Activation_NNP of_IN either_DT receptor_NN
          can_MD cross-desensitize_JJ the_DT other_JJ ,_, suggesting_VBG that_IN they_PRP
          share_VBP the_DT same_JJ G_NNP protein_NN pathway_NN ._.
          To_TO determine_VB the_DT effect_NN of_IN insulin_NN receptor_NN or_CC IGF-_NNP 1_CD
          receptor_NN activation_NN on_IN GPCR_NNP 's_POS ,_, cells_NNS were_VBD treated_VBN with_IN
          insulin_NN or_CC IGF-_NNP 1_CD ._. The_DT Cl_NNP -_: currents_NNS elicited_JJ by_IN subsequent_JJ
          5_CD -_: HT_NNP or_CC Ach_NNP stimulation_NN were_VBD compared_VBN with_IN those_DT without_IN
          insulin_NN /_NN IGF-_NNP 1_CD treatment_NN ._. As_IN shown_VBN in_IN Fig_NNP ._. 2_LS ,_, treatment_NN
          with_IN insulin_NN or_CC IGF-_NNP 1_CD resulted_VBD in_IN a_DT significant_JJ reduction_NN
          of_IN the_DT peak_JJ Cl_NNP -_: current_JJ in_IN response_NN to_TO 5_CD -_: HT_NNP ,_, but_CC did_VBD not_RB
          affect_VB the_DT response_NN to_TO Ach_NNP ._. Insulin_NNP alone_RB did_VBD not_RB induce_VB
          an_DT ionic_JJ current_NN under_IN these_DT conditions_NNS (_( data_NNS not_RB shown_VBN )_) ._.
          Insulin_NNP treatment_NN did_VBD not_RB affect_VB the_DT general_JJ
          characteristics_NNS of_IN the_DT Cl_NNP -_: current_JJ induced_VBN by_IN 5_CD -_: HT_NNP or_CC
          Ach_NNP ,_, i_NNP ._. e_SYM ._. ,_, a_DT depolarizing_VBG current_JJ with_IN a_DT rapid_JJ transient_JJ
          peak_NN and_CC slower_JJR oscillatory_NN phase_NN (_( Figs_NNP ._. 2_LS aand_NN 2_CD b_SYM ,_, top_JJ )_) ._.
          Instead_RB ,_, insulin_NN specifically_RB reduced_VBD the_DT peak_JJ Cl_NNP
          -_: current_JJ in_IN response_NN to_TO 5_CD -_: HT_NNP by_IN 83_CD %_NN compared_VBN to_TO untreated_JJ
          controls_NNS (_( 1513_CD ±_NN 138_CD nA_NN vs_NNS ._. 261_CD ±_NN 78_CD nA_NN ,_, Fig_NNP ._. 2_LS a_DT ,_, middle_JJ )_)
          with_IN no_DT change_NN in_IN the_DT magnitude_NN of_IN the_DT Cl_NNP -_: current_JJ in_IN
          response_NN to_TO Ach_NNP (_( 2681_CD ±_NN 281_CD nA_NN vs_NNS ._. 2785_CD ±_NN 186_CD nA_NN ,_, Fig_NNP ._.
          2_LS b_SYM ,_, middle_JJ )_) ._. Similar_JJ to_TO the_DT effect_NN of_IN insulin_NN ,_, IGF-_NNP 1_CD
          treatment_NN specifically_RB reduced_VBD the_DT magnitude_NN of_IN the_DT Cl_NNP
          -_: current_JJ in_IN response_NN to_TO 5_CD -_: HT_NNP by_IN 56_CD %_NN (_( 1665_CD ±_NN 222_CD nA_NN vs_NNS ._.
          737_CD ±_NN 181_CD nA_NN ,_, Fig_NNP ._. 2_LS a_DT ,_, bottom_NN )_) ,_, without_IN affecting_VBG the_DT
          response_NN to_TO Ach_NNP (_( 1275_CD ±_NN 272_CD nA_NN vs_NNS ._. 1220_CD ±_NN 243_CD ,_, Fig_NNP ._. 2_LS b_SYM ,_,
          bottom_NN )_) ._. These_DT data_NNS indicate_VBP that_IN the_DT inhibitory_NN effect_NN
          of_IN insulin_NN /_NN IGF-_NNP 1_CD is_VBZ specific_JJ for_IN the_DT 5_CD -_: HT_NNP 
          2_CD C_NNP receptor_NN ._.
          Insulin_NNP and_CC IGF-_NNP 1_CD receptors_NNS activate_VBP several_JJ different_JJ
          regulatory_JJ proteins_NNS ,_, including_VBG RAS_NNP ,_, MAP_NNP kinase_NN ,_, PI_NNP 3_CD
          kinase_NN ,_, S_NNP 6_CD kinase_NN and_CC protein_NN tyrosine_NN phosphatase_NN [_NN 6_CD 7_CD
          17_CD ]_NN ._. Initiation_NNP of_IN this_DT transduction_NN cascade_NN requires_VBZ
          the_DT intrinsic_JJ tyrosine_NN kinase_NN activity_NN of_IN the_DT
          insulin_NN /_NN IGF-_NNP 1_CD receptors_NNS ._. To_TO determine_VB whether_IN or_CC not_RB
          tyrosine_NN kinase_NN activity_NN was_VBD required_VBN for_IN the_DT action_NN of_IN
          insulin_NN /_NN IGF-_NNP 1_CD ,_, the_DT tyrosine_NN kinase_NN inhibitor_NN genistein_NN
          was_VBD used_VBN ._. As_IN shown_VBN in_IN Fig_NNP ._. 3_LS a_DT ,_, in_IN oocytes_NNS pretreated_JJ with_IN
          genistein_NN before_IN IGF-_NNP 1_CD administration_NN ,_, the_DT reduction_NN in_IN
          5_CD -_: HT-induced_NNP Cl_NNP -_: current_NN was_VBD abolished_VBN ,_, whereas_IN genistein_NN
          treatment_NN alone_RB had_VBD no_DT effect_NN on_IN the_DT 5_CD -_: HT_NNP response_NN in_IN
          oocytes_NNS not_RB treated_VBN with_IN IGF-_NNP 1_CD ._.
          The_DT insulin_NN /_NN IGF-_NNP 1_CD pathway_NN diverges_NNS into_IN RAS-dependent_NNP
          and_CC -_: independent_JJ paths_NNS ._. To_TO identify_VB which_WDT path_NN is_VBZ
          involved_VBN ,_, an_DT anti-_NN RAS_NNP antibody_NN that_WDT can_MD neutralize_NN RAS_NNP
          activity_NN was_VBD injected_VBN into_IN oocytes_NNS before_IN IGF-_NNP 1_CD
          treatment_NN ._. This_DT RAS_NNP antibody_NN (_( Y_NNP 13_CD -_: 259_CD )_) has_VBZ been_VBN shown_VBN in_IN
          oocytes_NNS to_TO block_VB the_DT re-entry_JJ into_IN meiosis_NNS or_CC germinal_NN
          vesicle_NN breakdown_NN induced_VBN by_IN IGF-_NNP 1_CD [_NN 18_CD ]_NN ._. Antibody_NNP
          injection_NN blocked_VBD the_DT effect_NN of_IN IGF-_NNP 1_CD on_IN the_DT 5_CD -_: HT_NNP
          response_NN (_( Fig_NNP ._. 3_LS b_SYM )_) ,_, demonstrating_VBG that_IN the_DT inhibitory_NN
          effect_NN of_IN insulin_NN /_NN IGF-_NNP 1_CD was_VBD RAS-dependent_NNP ._.
          RAS_NNP activates_NNS a_DT cascade_NN of_IN kinases_NNS ,_, including_VBG RAF_NNP ,_, MAP_NNP
          kinase_NN kinase_NN (_( MEK_NNP )_) and_CC MAP_NNP kinase_NN ._. The_DT involvement_NN of_IN
          this_DT pathway_NN in_IN regulation_NN of_IN 5_CD -_: HT_NNP receptor_NN function_NN was_VBD
          examined_VBN ._. Pretreating_NNP cells_NNS with_IN PD_NNP 098059_CD ,_, a_DT specific_JJ
          MEK_NNP kinase_NN inhibitor_NN [_NN 19_CD ]_NN ,_, blocked_VBD the_DT effect_NN of_IN IGF-_NNP 1_CD
          on_IN the_DT 5_CD -_: HT_NNP response_NN ,_, whereas_IN inhibition_NN of_IN protein_NN
          kinase_NN C_NNP did_VBD not_RB (_( Fig_NNP ._. 4_LS a_DT )_) ._. These_DT results_NNS suggest_VBP that_IN
          MEK_NNP is_VBZ involved_VBN in_IN mediating_VBG the_DT inhibitory_NN effect_NN of_IN the_DT
          insulin_NN /_NN IGF-_NNP 1_CD pathway_NN ._.
          MEK_NNP 's_POS primary_JJ role_NN is_VBZ activation_NN of_IN MAP_NNP kinase_NN through_IN
          threonine_NN and_CC tyrosine_NN phosphorylation_NN of_IN MAP_NNP kinase_NN
          which_WDT in_IN turn_NN phosphorylates_NNS and_CC regulates_VBZ the_DT function_NN
          of_IN several_JJ nuclear_JJ proteins_NNS ,_, such_JJ as_IN transcription_NN
          factors_NNS ,_, as_RB well_RB as_IN cytosolic_JJ and_CC membrane-associated_JJ
          proteins_NNS ,_, such_JJ as_IN the_DT insulin_NN and_CC EGF_NNP receptors_NNS ._. To_TO
          determine_VB whether_IN MAP_NNP kinase_NN is_VBZ involved_VBN in_IN mediating_VBG the_DT
          insulin_NN /_NN IGF-_NNP 1_CD effect_NN ,_, activated_VBN MAP_NNP kinase_NN [_NN 20_CD ]_NN was_VBD
          injected_VBN into_IN oocytes_NNS before_IN testing_VBG the_DT 5_CD -_: HT_NNP response_NN ._.
          Active_JJ MAP_NNP kinase_NN reduced_VBD the_DT 5_CD -_: HT_NNP response_NN by_IN 56_CD %_NN
          compared_VBN to_TO untreated_JJ controls_NNS (_( Fig_NNP ._. 4_LS b_SYM )_) ,_, demonstrating_VBG
          that_IN active_JJ MAP_NNP kinase_NN is_VBZ capable_JJ of_IN mimicking_VBG the_DT
          inhibitory_NN effect_NN of_IN insulin_NN /_NN IGF-_NNP 1_CD on_IN the_DT 5_CD -_: HT_NNP 
          2_CD C_NNP receptor_NN ._.
          The_DT 5_CD -_: HT_NNP 
          2_CD C_NNP receptor_NN contains_VBZ a_DT putative_JJ MAP_NNP
          kinase_NN site_NN [_NN 21_CD ]_NN at_IN serine_NN 159_CD in_IN the_DT second_JJ
          intracellular_NN loop_NN between_IN the_DT 3_CD rd_NN and_CC 4_CD th_NN transmembrane_NN
          domains_NNS ._. To_TO ascertain_VB whether_IN MAP_NNP kinase_NN directly_RB
          modulates_NNS the_DT receptor_NN function_NN ,_, this_DT amino_JJ acid_NN was_VBD
          changed_VBN to_TO alanine_NN by_IN site-directed_JJ mutagenesis_NNS ._. As_IN shown_VBN
          in_IN Fig_NNP ._. 4_LS c_SYM ,_, insulin_NN no_RB longer_RB inhibited_VBD the_DT peak_JJ Cl_NNP
          -_: current_JJ activated_VBN by_IN the_DT mutant_JJ receptor_NN S_NNP 159_CD A_DT ,_,
          indicating_VBG that_DT serine_NN 159_CD is_VBZ likely_JJ the_DT site_NN of_IN MAP_NNP
          kinase_NN modulation_NN ._.
        
      
      
        Discussion_NNP
        The_DT 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN is_VBZ a_DT member_NN of_IN the_DT G_NNP
        protein-coupled_JJ receptor_NN superfamily_RB and_CC one_CD of_IN over_IN 30_CD
        cloned_VBN serotonin_NN receptors_NNS ._. Except_IN for_IN the_DT 5_CD -_: HT_NNP 
        3_CD receptor_NN which_WDT is_VBZ an_DT oligomeric_JJ ion_NN
        channel_NN ,_, all_DT serotonin_NN receptors_NNS are_VBP GPCRs_NNP and_CC are_VBP divided_VBN
        into_IN seven_CD subfamilies_NNS based_VBN on_IN sequence_NN homology_NN ,_, gene_NN
        structure_NN ,_, and_CC signaling_VBG pathways_NNS [_NN 22_CD 23_CD ]_NN ._. The_DT 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN ,_, like_IN other_JJ members_NNS of_IN the_DT
        5_CD -_: HT_NNP 
        2_CD family_NN ,_, stimulates_NNS phospholipase_NN C_NNP ,_,
        and_CC increases_NNS IP_NNP 
        3_CD and_CC DAG_NNP which_WDT leads_VBZ to_TO increased_VB
        intracellular_NN calcium_NN and_CC mediates_NNS many_JJ cellular_JJ processes_NNS ._.
        In_IN general_JJ 5_CD -_: HT_NNP 
        2_CD receptor_NN types_NNS are_VBP growth-regulatory_JJ
        and_CC stimulate_VB cell_NN division_NN ._. However_RB ,_, unlike_IN the_DT 5_CD -_: HT_NNP 
        2_CD A_DT [_NN 24_CD ]_NN and_CC 5_CD -_: HT_NNP 
        2_CD B_NNP [_NN 25_CD ]_NN receptors_NNS ,_, the_DT 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN is_VBZ not_RB known_VBN to_TO activate_VBP MAP_NNP
        kinase_NN ._. The_DT 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN activates_NNS multiple_JJ signal_NN
        transduction_NN cascades_NNS 
        in_IN vivo_NN and_CC in_IN heterologous_JJ
        expression_NN systems_NNS (_( see_VB Raymond_NNP et_CC al_NN 2001_CD [_NN 22_CD ]_NN ;_: and_CC
        Gerhardt_NNP and_CC van_NN Heerikhuizen_NNP ,_, 1997_CD (_( [_NN 5_CD ]_NN ,_, for_IN reviews_NNS )_) ._.
        In_IN choroid_NN plexus_JJ ,_, the_DT 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN stimulates_NNS PI_NNP turnover_NN ,_,
        increases_NNS cGMP_NN formation_NN and_CC activates_NNS Cl_NNP -_: channels_NNS ._. In_IN
        heterologous_JJ expression_NN systems_NNS ,_, the_DT 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN can_MD couple_NN to_TO two_CD different_JJ
        K_NNP +_NN channels_NNS [_NN 26_CD ]_NN and_CC in_IN some_DT cases_NNS either_CC activation_NN or_CC
        inactivation_NN of_IN adenylyl_NN cyclase_NN has_VBZ been_VBN demonstrated_VBN in_IN
        addition_NN to_TO the_DT well-known_JJ activation_NN of_IN phospholipase_NN C_NNP
        and_CC PI_NNP turnover_NN ._.
        The_DT regulation_NN of_IN the_DT 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN has_VBZ been_VBN the_DT focus_NN of_IN
        several_JJ studies_NNS ,_, but_CC the_DT results_NNS have_VBP been_VBN difficult_JJ to_TO
        interpret_VB for_IN several_JJ reasons_NNS including_VBG the_DT complex_JJ
        pharmacology_NN of_IN this_DT receptor_NN ._. The_DT presence_NN of_IN spare_JJ 5_CD -_: HT_NNP 
        2_CD C_NNP receptors_NNS [_NN 27_CD ]_NN in_IN choroid_NN plexus_JJ
        has_VBZ also_RB complicated_VBN the_DT study_NN of_IN desensitization_NN 
        in_IN vivo_NN ._. However_RB ,_, it_PRP has_VBZ been_VBN
        demonstrated_VBN that_DT denervation_NN of_IN 5_CD -_: HT_NNP neurons_NNS
        supersensitizes_NNS 5_CD -_: HT_NNP 
        2_CD C_NNP receptors_NNS [_NN 28_CD ]_NN in_IN choroid_NN plexus_JJ ,_,
        suggesting_VBG that_IN these_DT receptors_NNS are_VBP under_IN tonic_NN control_NN by_IN
        5_CD -_: HT_NNP ._. In_IN primary_JJ cultures_NNS of_IN choroid_NN plexus_JJ cells_NNS ,_, repeated_VBD
        5_CD -_: HT_NNP application_NN desensitizes_NNS 5_CD -_: HT_NNP induced_VBD increases_NNS in_IN
        intracellular_NN calcium_NN [_NN 13_CD ]_NN ._. Down-regulation_NNP of_IN receptor_NN
        binding_JJ sites_NNS in_IN choroid_NN plexus_JJ cells_NNS is_VBZ seen_VBN after_IN agonist_NN
        treatment_NN [_NN 29_CD ]_NN ._. However_RB ,_, inverse_NN agonists_NNS can_MD either_CC
        down-_NN [_NN 29_CD ]_NN or_CC up-regulate_JJ [_NN 30_CD ]_NN 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN binding_JJ sites_NNS dependent_JJ upon_IN
        cellular_JJ context_NN ._. The_DT mechanisms_NNS underlying_VBG desensitization_NN
        or_CC down-regulation_JJ of_IN the_DT 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN are_VBP unknown_JJ but_CC these_DT
        reports_NNS suggest_VBP finely_RB tuned_VBN control_NN of_IN 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN function_NN and_CC density_NN ._.
        Several_JJ studies_NNS have_VBP utilized_JJ heterologous_JJ expression_NN
        systems_NNS to_TO identify_VB mechanisms_NNS of_IN 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN regulation_NN ._. Phosphorylation_NNP
        most_RBS likely_JJ has_VBZ a_DT prominent_JJ role_NN in_IN regulation_NN of_IN the_DT 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN ._. Westphal_NNP and_CC colleagues_NNS [_NN
        31_CD ]_NN demonstrated_VBN that_IN the_DT 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN exhibits_VBZ basal_NN
        phosphorylation_NN ,_, and_CC that_DT agonist_NN treatment_NN was_VBD associated_VBN
        with_IN increased_VBN phosphorylation_NN and_CC receptor_NN desensitization_NN
        in_IN transfected_JJ cells_NNS ._. The_DT expressed_VBD 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN exhibits_VBZ homologous_RB and_CC
        heterologous_JJ desensitization_NN in_IN oocytes_NNS [_NN 32_CD ]_NN mediated_JJ by_IN
        protein_NN kinase_NN C_NNP [_NN 33_CD 34_CD 35_CD ]_NN ._. A_DT calmodulin-dependent_JJ
        kinase_NN may_MD also_RB be_VB involved_VBN in_IN homologous_RB desensitization_NN [_NN
        36_CD ]_NN ._. In_IN contrast_NN ,_, a_DT recent_JJ study_NN indicates_VBZ that_IN neither_DT
        PKC_NNP nor_CC calmodulin-dependent_JJ protein_NN kinase_NN II_NNP are_VBP
        involved_VBN ,_, instead_RB desensitization_NN of_IN the_DT 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN is_VBZ dependent_JJ on_IN GRK_NNP activity_NN
        [_NN 37_CD ]_NN ._. Interestingly_RB ,_, tyrosine_NN kinase_NN involvement_NN in_IN the_DT
        agonist-mediated_JJ phosphorylation_NN of_IN the_DT rat_NN 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN has_VBZ also_RB been_VBN reported_VBN [_NN 38_CD
        ]_NN ,_, although_IN as_IN yet_RB no_DT report_NN has_VBZ shown_VBN that_IN the_DT 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN directly_RB activates_NNS tyrosine_NN
        kinases_NNS ._.
        The_DT 5_CD -_: HT_NNP 
        2_CD C_NNP receptors_NNS are_VBP subject_JJ to_TO another_DT form_NN
        of_IN regulation_NN by_IN means_NNS of_IN mRNA_NN editing_NN [_NN 39_CD ]_NN ._. RNA_NNP editing_NN
        [_NN 40_CD ]_NN is_VBZ a_DT type_NN of_IN posttranscriptional_NN modification_NN that_WDT
        occurs_VBZ when_WRB double-stranded_JJ RNA_NNP deaminase_NN converts_VBZ
        genomically_RB coded_VBN adenosines_NNS to_TO inosines_NNS ,_, thereby_RB changing_VBG
        the_DT coding_VBG sequence_NN of_IN specific_JJ RNA_NNP transcripts_NNS ._. RNA_NNP
        editing_NN of_IN the_DT rat_NN 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN was_VBD first_RB described_VBN by_IN Burns_NNP
        et_CC al_NN ._. [_NN 39_CD ]_NN and_CC editing_NN at_IN four_CD nucleotide_NN sites_NNS alters_NNS
        three_CD amino_JJ acids_NNS within_IN the_DT second_JJ intracellular_NN loop_NN ._. RNA_NNP
        editing_NN of_IN the_DT 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN is_VBZ conserved_JJ among_IN species_NNS [_NN
        41_CD ]_NN and_CC at_IN least_JJS 7_CD major_JJ isoforms_NNS with_IN tissue-specific_JJ
        expression_NN patterns_NNS have_VBP been_VBN described_VBN in_IN rat_NN brain_NN [_NN 39_CD ]_NN
        suggesting_VBG a_DT functional_JJ importance_NN ._. The_DT mouse_NN cDNA_NN clone_NN
        used_VBN in_IN our_PRP$ study_NN codes_NNS for_IN the_DT fully_RB edited_JJ form_NN
        (_( Val_NNP 157_CD -_: Ser_NNP 159_CD -_: Val_NNP 161_CD )_) of_IN the_DT receptor_NN ._. The_DT putative_JJ MAP_NNP
        kinase_NN site_NN (_( Ser_NNP 159_CD )_) we_PRP identified_VBD and_CC mutated_VBN in_IN this_DT
        study_NN is_VBZ also_RB a_DT site_NN of_IN mRNA_NN editing_NN in_IN this_DT receptor_NN ;_: i_NNP ._. e_SYM ._.
        Ser_NNP 159_CD is_VBZ only_RB present_JJ in_IN edited_JJ forms_NNS ._. The_DT fully_RB edited_JJ
        rat_NN 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN exhibits_VBZ reduced_VBN agonist_NN
        efficacy_NN or_CC ability_NN to_TO interact_NN with_IN G_NNP proteins_NNS compared_VBN to_TO
        the_DT unedited_JJ receptor_NN (_( Ile_NNP 157_CD -_: Asn_NNP 159_CD -_: Ile_NNP 161_CD )_) in_IN transfected_JJ
        cells_NNS [_NN 39_CD ]_NN ._. Interestingly_RB ,_, 5_CD -_: HT_NNP elicits_NNS a_DT larger_JJR
        response_NN (_( see_VB Fig_NNP ._. 4_LS c_SYM )_) in_IN cells_NNS expressing_VBG the_DT mutant_JJ
        receptor_NN (_( S_NNP 159_CD A_DT )_) compared_VBN to_TO the_DT fully_RB edited_JJ mouse_NN
        receptor_NN ,_, and_CC the_DT mutant_JJ receptor_NN is_VBZ not_RB regulated_VBN by_IN
        insulin_NN ._. Binding_NNP of_IN radiolabelled_JJ mesulergine_NN was_VBD similar_JJ
        in_IN the_DT edited_JJ 5_CD -_: HT_NNP 
        2_CD C_NNP and_CC S_NNP 159_CD A_DT mutant_JJ receptors_NNS in_IN
        transfected_JJ cells_NNS (_( data_NNS not_RB shown_VBN )_) ._. These_DT results_NNS suggest_VBP
        some_DT intriguing_JJ possibilities_NNS ._. Either_CC the_DT mutant_JJ receptor_NN
        (_( S_NNP 159_CD A_DT )_) couples_NNS more_RBR readily_RB to_TO G_NNP proteins_NNS compared_VBN to_TO the_DT
        fully_RB edited_JJ 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN ,_, or_CC the_DT edited_JJ (_( Ser_NNP 159_CD
        containing_VBG )_) receptor_NN may_MD be_VB phosphorylated_JJ to_TO some_DT extent_NN
        in_IN the_DT basal_NN state_NN ._. We_PRP hypothesize_NN that_IN the_DT phosphorylated_JJ
        receptor_NN may_MD couple_NN less_RBR efficiently_RB to_TO G_NNP proteins_NNS ,_, but_CC
        this_DT hypothesis_NNS remain_VBP to_TO be_VB tested_VBN ._. Our_PRP$ results_NNS indirectly_RB
        suggest_VBP that_IN 5_CD -_: HT_NNP 
        2_CD C_NNP receptors_NNS containing_VBG Ser_NNP 159_CD may_MD be_VB
        subject_JJ to_TO yet_RB another_DT form_NN of_IN regulation_NN ;_: i_NNP ._. e_SYM ._. ,_,
        phosphorylation_NN by_IN MAP_NNP kinase_NN ._.
        The_DT 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN is_VBZ very_RB abundant_JJ in_IN choroid_NN
        plexus_JJ [_NN 8_CD 42_CD ]_NN ,_, and_CC is_VBZ the_DT only_RB 5_CD -_: HT_NNP receptor_NN present_JJ on_IN
        these_DT cells_NNS ._. Choroid_NNP plexus_JJ cells_NNS line_VBP the_DT cerebral_JJ
        ventricles_NNS ,_, form_NN the_DT blood-_NN CSF_NNP barrier_NN ,_, and_CC are_VBP responsible_JJ
        for_IN the_DT production_NN of_IN cerebrospinal_NN fluid_JJ (_( CSF_NNP )_) [_NN 43_CD ]_NN ._.
        Although_IN the_DT mechanisms_NNS have_VBP not_RB been_VBN delineated_JJ ,_, the_DT 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN is_VBZ thought_VBN to_TO regulate_VB CSF_NNP
        production_NN and_CC the_DT expression_NN of_IN transferrin_NN ._. For_IN example_NN ,_,
        upon_IN intraventricular_NN injection_NN ,_, 5_CD -_: HT_NNP 
        2_CD C_NNP agonists_NNS decrease_VBP the_DT production_NN of_IN
        CSF_NNP [_NN 44_CD ]_NN and_CC in_IN primary_JJ cultures_NNS of_IN choroid_NN plexus_JJ ,_, 5_CD -_: HT_NNP
        agonists_NNS increase_VBP the_DT expression_NN of_IN transferrin_NN [_NN 45_CD 46_CD ]_NN ,_,
        an_DT iron_NN carrier_NN protein_NN which_WDT has_VBZ trophic_JJ effects_NNS on_IN the_DT
        brain_NN ._. In_IN addition_NN ,_, choroid_NN plexus_JJ expresses_VBZ insulin_NN ,_,
        IGF-I_NNP ,_, and_CC IGF-II_NNP receptors_NNS [_NN 11_CD 47_CD ]_NN ._. ,_, as_RB well_RB as_IN large_JJ
        amounts_NNS of_IN IGF-II_NNP that_WDT is_VBZ secreted_JJ into_IN the_DT CSF_NNP [_NN 47_CD ]_NN ._.
        CSF_NNP contains_VBZ insulin_NN /_NN IGFs_NNP and_CC 5_CD -_: HT_NNP [_NN 48_CD ]_NN in_IN concentrations_NNS
        high_JJ enough_RB to_TO activate_VBP their_PRP$ respective_JJ receptors_NNS in_IN
        choroid_NN plexus_JJ ,_, suggesting_VBG that_IN this_DT signaling_VBG mechanism_NN
        may_MD occur_VB 
        in_IN vivo_NN ._. It_PRP has_VBZ been_VBN suggested_VBN that_IN
        5_CD -_: 5_CD HT_NNP 
        2_CD C_NNP receptors_NNS in_IN choroid_NN plexus_JJ may_MD be_VB
        tonically_RB activated_VBN ,_, due_JJ to_TO CSF_NNP 5_CD -_: HT_NNP concentrations_NNS near_IN
        the_DT EC_NNP 
        50_CD ,_, thus_RB tonically_RB inhibiting_VBG CSF_NNP
        production_NN ._. Our_PRP$ data_NNS suggest_VBP that_DT insulin_NN may_MD reduce_VB 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN activity_NN ,_, thereby_RB increasing_VBG
        CSF_NNP production_NN and_CC decreasing_VBG transferrin_NN production_NN ._. As_IN a_DT
        consequence_NN ,_, insulin_NN inhibition_NN of_IN 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN activity_NN may_MD change_VB the_DT
        volume_NN and_CC composition_NN of_IN CSF_NNP and_CC indirectly_RB may_MD alter_VB the_DT
        concentrations_NNS of_IN many_JJ potentially_RB important_JJ signaling_VBG
        molecules_NNS in_IN CSF_NNP ._.
        MAP_NNP kinase_NN regulation_NN is_VBZ potentially_RB an_DT important_JJ
        mechanism_NN of_IN modulating_VBG GPCR_NNP function_NN ,_, however_RB the_DT
        prevalence_NN of_IN this_DT type_NN of_IN modulation_NN is_VBZ unknown_JJ ._. Our_PRP$
        results_NNS suggest_VBP that_IN the_DT 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN is_VBZ a_DT MAP_NNP kinase_NN substrate_NN ,_,
        whereas_IN the_DT M_NNP 1_CD Ach_NNP receptor_NN is_VBZ not_RB ._. The_DT optimal_NN consensus_NN
        site_NN for_IN MAP_NNP kinase_NN phosphorylation_NN isPro-X-_JJ (_( Ser_NNP /_NN Thr_NNP )_) -_: Pro_FW ,_,
        however_RB in_IN some_DT cases_VBZ the_DT upstream_RB Pro_FW is_VBZ not_RB required_VBN and_CC
        a_DT minimal_JJ sequence_NN of_IN Ser-_NNP Pro_FW or_CC Thr-_NNP Pro_FW is_VBZ phosphorylated_JJ
        (_( for_IN review_NN ,_, see_VB Davis_NNP ,_, 1993_CD [_NN 21_CD ]_NN )_) ._. The_DT 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN site_NN is_VBZ just_RB such_JJ a_DT minimal_JJ
        sequence_NN of_IN Ser-_NNP Pro_FW and_CC it_PRP is_VBZ the_DT only_RB MAP_NNP kinase_NN site_NN we_PRP
        identified_VBD within_IN the_DT receptor_NN 's_POS presumed_VBN intracellular_NN
        domains_NNS ._. This_DT site_NN is_VBZ not_RB conserved_JJ within_IN the_DT M_NNP 1_CD Ach_NNP
        receptor_NN or_CC other_JJ 5_CD -_: HT_NNP 
        2_CD type_NN receptors_NNS ._. Although_IN all_DT of_IN these_DT
        receptors_NNS contain_VBP Ser-_NNP Pro_FW or_CC Thr-_NNP Pro_FW sequences_NNS within_IN
        intracellular_NN domains_NNS it_PRP is_VBZ difficult_JJ to_TO determine_VB the_DT
        importance_NN of_IN these_DT sites_NNS ._. For_IN example_NN ,_, despite_IN the_DT fact_NN
        that_DT insulin_NN did_VBD not_RB inhibit_VB Ach_NNP receptor_NN signaling_VBG in_IN our_PRP$
        experiment_NN ,_, the_DT rat_NN M_NNP 1_CD Ach_NNP receptor_NN contains_VBZ several_JJ MAP_NNP
        kinase_NN sites_NNS ,_, including_VBG one_CD Thr-_NNP Pro_FW sequence_NN in_IN the_DT 2_CD
        ndintracellular_NN loop_NN and_CC 3_CD Ser-_NNP Pro_FW and_CC one_CD Thr-_NNP Pro_FW in_IN the_DT 3_CD
        rdintracellular_NN loop_NN ._. The_DT reason_NN for_IN this_DT apparent_JJ
        discrepancy_NN is_VBZ unclear_JJ but_CC may_MD be_VB related_VBN to_TO a_DT "_'' spare_JJ
        receptor_NN "_'' phenomenon_NN in_IN the_DT oocyte_NN expression_NN system_NN ._.
        Alternatively_RB ,_, additional_JJ sequence_NN or_CC regulatory_JJ elements_NNS ,_,
        which_WDT have_VBP not_RB been_VBN identified_VBN ,_, may_MD be_VB required_VBN for_IN MAP_NNP
        kinase_NN phosphorylation_NN ._. Determining_VBG the_DT prevalence_NN and_CC
        specificity_NN of_IN MAP_NNP kinase_NN modulation_NN of_IN GPCR_NNP 's_POS will_MD await_VB
        future_JJ studies_NNS ._.
      
      
        Conclusions_NNP
        Taken_VBN together_RB ,_, our_PRP$ results_NNS demonstrate_VBP that_DT
        insulin_NN /_NN IGF-_NNP 1_CD signaling_VBG down-regulates_JJ 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN function_NN in_IN choroid_NN plexus_JJ
        and_CC 
        Xenopus_NNP oocytes_NNS via_IN MAP_NNP kinase_NN ,_, and_CC
        that_IN the_DT 5_CD -_: HT_NNP 
        2_CD C_NNP receptor_NN is_VBZ a_DT substrate_NN for_IN MAP_NNP
        kinase_NN ._. To_TO our_PRP$ knowledge_NN ,_, this_DT is_VBZ the_DT first_JJ description_NN of_IN
        MAP_NNP kinase_NN regulation_NN of_IN a_DT GPCR_NNP and_CC suggests_VBZ that_IN this_DT form_NN
        of_IN regulation_NN may_MD be_VB more_RBR wide-spread_JJ than_IN has_VBZ been_VBN
        previously_RB recognized_VBN ._. Furthermore_RB ,_, since_IN some_DT GPCRs_NNP can_MD
        modulate_VBP MAP_NNP kinase_NN activity_NN ,_, MAP_NNP kinase_NN regulation_NN of_IN GPCR_NNP
        function_NN may_MD then_RB serve_VB as_IN a_DT form_NN of_IN negative_JJ feedback_NN
        control_NN in_IN much_RB the_DT same_JJ way_NN that_DT protein_NN kinase_NN A_DT ,_, protein_NN
        kinase_NN C_NNP and_CC the_DT G_NNP protein-coupled_JJ receptor_NN kinases_NNS (_( GRKs_NNP )_)
        regulate_VB GPCRs_NNP ._.
      
      
        Methods_NNP
        
          Chemicals_NNS and_CC Reagents_NNP
          Cell_NNP culture_NN reagents_NNS and_CC enzymes_NNS including_VBG MEM_NNP ,_, HAM_NNP 's_POS
          F_NN 12_CD ,_, D-_NNP valine_NN ,_, dialyzed_JJ fetal_JJ calf_NN serum_NN ,_, Pronase_NNP and_CC
          DNase_NNP I_PRP are_VBP from_IN Life_NNP Technologies_NNPS (_( Grand_NNP Island_NNP ,_, NY_NNP )_)
          except_IN as_IN noted_VBN ._. All_DT other_JJ chemicals_NNS are_VBP from_IN Sigma_NNP (_( St_NNP ._.
          Louis_NNP ,_, MO_NNP )_) except_IN as_IN noted_VBN ._. PD_NNP 098059_CD was_VBD kindly_RB provided_VBN
          by_IN Dr_NNP ._. A_DT ._. R_NN ._. Saltiel_NNP (_( Parke-_NNP Davis_NNP Pharmaceutical_NNP
          Research_NNP ,_, Ann_NNP Arbor_NNP ,_, Michigan_NNP )_) ._. Purified_NNP ERK_NNP 2_CD was_VBD kindly_RB
          provided_VBN by_IN Dr_NNP ._. M_NNP ._. H_NNP ._. Cobb_NNP (_( Department_NNP of_IN Pharmacology_NNP ,_,
          UT_NNP Southwestern_NNP Medical_NNP Center_NNP ,_, Dallas_NNP ,_, TX_NNP )_) ._.
        
        
          Choroid_NNP plexus_JJ cell_NN isolation_NN and_CC culture_NN
          All_DT animal_NN experiments_NNS in_IN this_DT work_NN have_VBP been_VBN carried_VBN
          out_IN in_IN accordance_NN with_IN the_DT Guide_NNP for_IN the_DT Care_NNP and_CC Use_NN of_IN
          Laboratory_NNP Animals_NNPS as_IN required_VBN by_IN the_DT U_NNP ._. S_NNP ._. National_NNP
          Institutes_NNPS of_IN Health_NNP ._. Choroid_NNP plexus_JJ cells_NNS were_VBD isolated_VBN
          as_IN described_VBN [_NN 46_CD ]_NN ._. Briefly_NNP ,_, choroid_NN plexus_JJ from_IN adult_NN
          male_JJ Sprague-_NNP Dawley_NNP rats_NNS (_( 175_CD -_: 200_CD g_SYM )_) were_VBD dissected_VBN into_IN
          cold_JJ Locke_NNP 's_POS buffer_NN ,_, rinsed_JJ and_CC enzymatically_RB dissociated_JJ
          for_IN 10_CD minutes_NNS at_IN 37_CD °_NN C_NNP in_IN Hank_NNP 's_POS Balanced_NNP Salt_NNP Solution_NN
          (_( HBSS_NNP )_) containing_VBG 330_CD ug_NN /_NN ml_NN Pronase_NNP I_PRP and_CC 260_CD ug_NN /_NN ml_NN DNase_NNP
          I_PRP ._. The_DT cells_NNS were_VBD pelleted_JJ and_CC choroid_NN plexus_JJ cells_NNS were_VBD
          released_VBN after_IN an_DT additional_JJ digest_VB with_IN 130_CD ug_NN /_NN ml_NN DNase_NNP
          I_PRP in_IN HBSS_NNP ._. The_DT cells_NNS were_VBD resuspended_JJ in_IN MEM_NNP containing_VBG
          D-_NNP valine_NN and_CC 15_CD %_NN dialyzed_JJ fetal_JJ calf_NN serum_NN and_CC plated_JJ on_IN
          concavalin_NN A-_NNP coated_JJ round_NN glass_NN coverslips_NNS ._. Four_CD days_NNS
          later_RB the_DT media_NNS was_VBD replaced_VBN with_IN Ham_NNP 's_POS F_NN 12_CD medium_NN ._.
        
        
          Intracellular_NNP calcium_NN measurements_NNS
          After_IN 7_CD days_NNS in_IN culture_NN ,_, cells_NNS were_VBD loaded_VBN with_IN 1_CD ._. 5_CD μM_NN
          fura-_NN 2_CD AM_NNP (_( Molecular_NNP Probes_NNP ,_, Eugene_NNP ,_, OR_NNP )_) in_IN HBSS_NNP and_CC 1_CD
          mg_NN /_NN ml_NN bovine_JJ serum_NN albumin_NN (_( BSA_NNP )_) for_IN 30_CD minutes_NNS at_IN 22_CD °_NN C_NNP
          and_CC washed_VBN in_IN HBSS_NNP for_IN 30_CD minutes_NNS at_IN 22_CD °_NN C_NNP ._. Cells_NNP were_VBD
          continuously_RB superperfused_JJ with_IN HBSS_NNP containing_VBG the_DT
          indicated_VBD drugs_NNS ._. Insulin_NNP (_( 10_CD or_CC 20_CD μM_NN )_) was_VBD diluted_VBN into_IN
          HBSS_NNP containing_VBG 1_CD mg_NN /_NN ml_NN BSA_NNP ,_, and_CC 5_CD -_: HT_NNP (_( 2_CD uM_NN )_) was_VBD diluted_VBN
          into_IN HBSS_NNP ._. Some_DT cells_NNS were_VBD pretreated_JJ with_IN 50_CD μM_NN PD_NNP
          098059_CD for_IN 30_CD minutes_NNS before_IN intracellular_NN calcium_NN
          measurements_NNS ._. Fura_NNP imaging_NN was_VBD done_VBN using_VBG software_NN kindly_RB
          provided_VBN by_IN Dr_NNP ._. Eric_NNP Gruenstein_NNP of_IN University_NNP of_IN
          Cincinnati_NNP and_CC was_VBD carried_VBN out_IN as_RB previously_RB described_VBD [_NN
          49_CD ]_NN ._. Peak_NNP intracellular_NN calcium_NN responses_NNS were_VBD measured_VBN
          from_IN individual_JJ cells_NNS and_CC pooled_VBN for_IN statistical_JJ
          analysis_NN ._.
        
        
          Oocyte_NNP injection_NN and_CC drug_NN treatment_NN
          Oocytes_NNP were_VBD injected_VBN with_IN 
          in_IN vitro_NN transcribed_JJ RNA_NNP for_IN the_DT
          mouse_NN 5_CD -_: HT_NNP 
          2_CD C_NNP [_NN 50_CD ]_NN and_CC the_DT M_NNP 1_CD acetylcholine_NN
          (_( kindly_RB provided_VBN by_IN Dr_NNP ._. T_NN ._. Bonner_NNP )_) receptors_NNS for_IN the_DT
          experiment_NN in_IN Fig_NNP ._. 2_LS or_CC the_DT 5_CD -_: HT_NNP 
          2_CD C_NNP receptor_NN alone_RB for_IN all_DT other_JJ
          experiments_NNS ._. Three_CD days_NNS after_IN RNA_NNP injection_NN ,_, oocytes_NNS were_VBD
          stimulated_VBN with_IN 5_CD -_: HT_NNP or_CC Ach_NNP ,_, and_CC the_DT chloride_NN current_NN was_VBD
          measured_VBN using_VBG a_DT two-electrode_JJ voltage-clamp_JJ
          (_( Axoclamp-_NNP 2_CD A_DT ,_, Axon_NNP Instruments_NNP ,_, Foster_NNP City_NNP ,_, CA_NNP )_) ._. Oocytes_NNP
          were_VBD subjected_VBN to_TO different_JJ treatments_NNS as_IN follows_VBZ ._. For_IN
          insulin_NN or_CC IGF-_NNP 1_CD treatment_NN ,_, oocytes_NNS were_VBD treated_VBN with_IN 1_CD
          μM_NN insulin_NN or_CC 100_CD nM_NN IGF-_NNP 1_CD in_IN ND_NNP 96_CD (_( 96_CD mM_NN NaCl_NNP ,_, 2_CD mM_NN KCl_NNP ,_,
          1_CD mM_NN MgCl_NNP 
          2_CD ,_, 5_CD mM_NN HEPES_NNP ,_, pH_NN 7_CD ._. 6_CD )_) and_CC 1_CD mg_NN /_NN ml_NN
          BSA_NNP for_IN 5_CD minutes_NNS ,_, then_RB rinsed_JJ in_IN ND_NNP 96_CD for_IN 2_CD minutes_NNS
          before_IN stimulation_NN with_IN 1_CD μM_NN 5_CD -_: HT_NNP or_CC 10_CD μM_NN Ach_NNP ._. For_IN the_DT
          experiments_NNS in_IN Fig_NNP ._. 3_LS ,_, some_DT oocytes_NNS were_VBD pretreated_JJ with_IN
          1_CD μM_NN genistein_NN for_IN 60_CD minutes_NNS or_CC were_VBD injected_VBN with_IN RAS_NNP
          antibody_NN (_( 0_CD ._. 65_CD μg_NN /_NN 50_CD nl_NN )_) 5_CD minutes_NNS before_IN 5_CD -_: HT_NNP
          stimulation_NN or_CC treatment_NN with_IN IGF-_NNP 1_CD followed_VBN by_IN 5_CD -_: HT_NNP
          stimulation_NN ._. For_IN the_DT experiments_NNS in_IN Fig_NNP ._. 4_LS a_DT ,_, some_DT oocytes_NNS
          were_VBD pretreated_JJ with_IN either_DT PD_NNP 098059_CD [_NN 19_CD ]_NN (_( 50_CD μM_NN for_IN
          30_CD minutes_NNS )_) or_CC protein_NN kinase_NN C_NNP inhibitor_NN ,_, myristoylated_JJ
          EGF-R_NNP (_( Calbiochem_NNP ,_, La_NNP Jolla_NNP ,_, CA_NNP )_) ,_, (_( 5_CD μM_NN for_IN 30_CD minutes_NNS )_)
          before_IN 5_CD -_: HT_NNP stimulation_NN or_CC treatment_NN with_IN IGF-_NNP 1_CD followed_VBN
          by_IN stimulation_NN with_IN 5_CD -_: HT_NNP ._. In_IN Fig_NNP ._. 4_LS b_SYM ,_, some_DT oocytes_NNS were_VBD
          injected_VBN with_IN active_JJ MAP_NNP kinase_NN (_( ERK_NNP 2_CD ,_, 10_CD ng_NN /_NN cell_NN )_) or_CC MAP_NNP
          kinase_NN buffer_NN 5_CD minutes_NNS before_IN 5_CD -_: HT_NNP stimulation_NN or_CC
          treatment_NN with_IN IGF-_NNP 1_CD followed_VBN by_IN stimulation_NN with_IN 5_CD -_: HT_NNP ._.
          For_IN Fig_NNP ._. 4_LS c_SYM ,_, oocytes_NNS were_VBD injected_VBN with_IN 
          in_IN vitro_NN transcribed_JJ RNA_NNP for_IN the_DT
          5_CD -_: HT_NNP 
          2_CD C_NNP receptor_NN or_CC the_DT 5_CD -_: HT_NNP 
          2_CD C_NNP S_NNP 149_CD A_DT mutant_JJ receptor_NN ._. The_DT oocytes_NNS
          were_VBD stimulated_VBN with_IN 5_CD -_: HT_NNP or_CC treated_VBN with_IN insulin_NN
          followed_VBN by_IN stimulation_NN with_IN 5_CD -_: HT_NNP ._.
        
        
          Site-directed_NNP mutagenesis_NNS
          The_DT putative_JJ MAP_NNP kinase_NN site_NN on_IN the_DT 5_CD -_: HT_NNP 
          2_CD C_NNP receptor_NN ,_, serine_NN 159_CD ,_, was_VBD mutated_VBN
          to_TO alanine_NN by_IN PCR_NNP with_IN primers_NNS containing_VBG an_DT alanine_NN
          codon_NN at_IN the_DT place_NN for_IN serine_NN 159_CD ._. The_DT PCR_NNP product_NN was_VBD
          subcloned_JJ into_IN the_DT same_JJ vector_NN as_IN the_DT wild-type_JJ 5_CD -_: HT_NNP 
          2_CD C_NNP receptor_NN ,_, and_CC the_DT mutation_NN
          confirmed_VBN by_IN DNA_NNP sequencing_VBG ._.
        
      
      
        Authors_NNP '_'' contributions_NNS
        JH_NNP carried_VBD out_IN fura_NN imaging_NN and_CC oocyte_NN experiments_NNS and_CC
        drafted_VBD the_DT manuscript_NN ._. SZ_NNP participated_VBD in_IN fura_NN imaging_NN and_CC
        oocyte_NN experiments_NNS and_CC carried_VBD out_RP the_DT site-directed_JJ
        mutagenesis_NNS ._. LB_NNP participated_VBD in_IN oocyte_NN experiments_NNS ._. MM_NNP
        participated_VBD in_IN the_DT design_NN of_IN the_DT study_NN and_CC generated_VBD the_DT
        RAS_NNP antibody_NN ._. AD_NNP purified_JJ the_DT MAP_NNP kinase_NN and_CC participated_VBD
        in_IN the_DT design_NN of_IN the_DT study_NN ._. KG_NNP participated_VBD in_IN the_DT design_NN
        of_IN the_DT study_NN ._. AF_NNP participated_VBD in_IN the_DT fura_NN experiments_NNS and_CC
        in_IN the_DT design_NN of_IN the_DT study_NN ._. LY_NNP conceived_VBD of_IN the_DT study_NN and_CC
        participated_VBD in_IN its_PRP$ design_NN and_CC coordination_NN ._. All_DT authors_NNS
        read_VBP and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
